Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Unicycive Therapeutics Inc (UNCY)

Unicycive Therapeutics Inc (UNCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Unicycive Therapeutics Inc 4300 EL CAMINO REAL SUITE 210 LOS ALTOS CA 94022 USA

www.unicycive.com Employees: 23 P: 650-351-4495

Sector:

Medical

Description:

Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif.

Key Statistics

Overview:

Market Capitalization, $K 132,814
Enterprise Value, $K 106,674
Shares Outstanding, K 21,491
Annual Sales, $ 0 K
Annual Net Income, $ -36,730 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -6,010 K
EBIT, $ -31,550 K
EBITDA, $ -31,120 K
60-Month Beta 1.85
% of Insider Shareholders 10.71%
% of Institutional Shareholders 40.42%
Float, K 19,189
% Float 89.29%
Short Interest 1,434
Short Float 6.67%
Short Volume Ratio 0.81

Growth:

1-Year Return -11.65%
3-Year Return 24.22%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.39 on 11/12/25
Next Earnings Date 03/30/26
Earnings Per Share ttm -4.01
EPS Growth vs. Prev Qtr 25.00%
EPS Growth vs. Prev Year 22.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 06/20/25

UNCY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 9.77
Price/Earnings to Growth N/A
Return-on-Equity % -227.32%
Return-on-Assets % -117.71%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.91
Book Value/Share 2.12
Interest Coverage -523.71
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar